Hypersomnia
Hypersomnia is a condition in which you feel excessive sleepiness during the day. It may occur even after long stretches of sleep. Another name for hypersomnia is excessive daytime sleepiness (EDS). Hypersomnia can be a primary condition or a secondary condition.
Cluster Number:
Wiki Number: W098
Diagnosis: Hypersomnia
US Patients: 5-10%
World Patients:
Sex Ratio: M+;W
Age Onset:
Brain Area:
Symptoms: lack of alertness in daytime; prolonged night sleep for 3 months;sleep drunkenness-difficulty waking up;
Progression: Most other major diseases have hypersomnias and inability to have refreshing delta sleep at night.
Causes: narcolepsy, sleep apnea, reaction to medications,
Medications: modafinil is helpful.
Therapies: Using beds only for sleep and sex helps.
Youtube Video: Breakthroughs in the Management of
Idiopathic Hypersomnia
Amazon or Library Book: A Guide: How to Focus and be productive with oversleeping
Click the text to link or order from Amazon.
Support Group: hypersomniaalliance.com; 678-842-3512 (hypersomniafoundation.org)
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- The Lehigh Valley Health Network narcolepsy cohort: clinical and polysomnographic analysis of 304 casesby Rena Y Jiang on November 1, 2024
CONCLUSION: This is one of the largest monocentric studies to date of patients with narcolepsy and confirms the frequent comorbidities of narcolepsy. Specific clinical characteristics and comorbidities may help differentiate NT1 from NT2.
- Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic reviewby Clélia Quiles on October 31, 2024
Clozapine is effective in treatment-resistant schizophrenia but with adverse effects including sedation. Excessive daytime sleepiness, a symptom of hypersomnolence, is the most frequently reported subjective side-effect. The aim of this systematic review was to synthesise the literature evaluating the impact of clozapine on the objective assessment of hypersomnolence in people with schizophrenia. We systematically searched databases for articles evaluating hypersomnolence with...
- Regulation of wakefulness by neurotensin neurons in the lateral hypothalamusby Fumito Naganuma on October 31, 2024
The lateral hypothalamic region (LH) has been identified as a key region for arousal regulation, yet the specific cell types and underlying mechanisms are not fully understood. While neurons expressing orexins (OX) are considered the primary wake-promoting population in the LH, their loss does not reduce daily wake levels, suggesting the presence of additional wake-promoting populations. In this regard, we recently discovered that a non-OX cell group in the LH, marked by the expression of...
- Treatment of obstructive sleep apnea with CPAP improves daytime sleepiness and fatigue in cancer patientsby Kimia G Ganjaei on October 30, 2024
CONCLUSIONS: PAP therapy for OSA in cancer patients improves EDS and fatigue. Larger studies are necessary to evaluate the efficacy of PAP in improving fatigue in this population.